Project 4, RIG-1-like receptor regulation of T cell immunity against flavivirus
项目4、RIG-1样受体调节T细胞抗黄病毒免疫
基本信息
- 批准号:8675533
- 负责人:
- 金额:$ 51.58万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:Adaptor Signaling ProteinAntiviral AgentsCD8B1 geneCell SurvivalCellsCollaborationsCritical PathwaysCulicidaeDiamondEncephalitisEpidemicFlavivirusFlavivirus InfectionsGenerationsGoalsHumanImmuneImmune responseImmunityImmunologic MemoryInfectionJapanese encephalitis virusKnockout MiceKnowledgeLaboratoriesLifeMediatingMemoryMosquito-Borne EncephalitisMusNatural ImmunityProductionPropertyRNAReceptor SignalingRegulationRegulatory T-LymphocyteResourcesRoleSignal TransductionStagingT cell regulationT cell responseT memory cellT-Cell DevelopmentT-LymphocyteVaccinationVaccinesVirusVirus DiseasesWest Nile virusWorkadaptive immunitybiological systemscell mediated immune responsecytokinecytosolic receptorinsightmemory recallnew therapeutic targetnovelpathogenpreventprogramsreceptorresponse
项目摘要
The goal of Project 4 is to understand the crosstalk between innate immune sensing and regulation of protective T cell immune response during flavivirus infection. West Nile virus (WNV) and Japanese encephalitis virus (JEV) are emerging mosquito-borne flaviviruses that globally cause annual epidemics of virus-induced encephalitis. T here is no approved vaccine or therapy for use in humans to treat WNV infection and the current vaccines to prevent JEV infection do not provide life-long protective immunity. Protection against WNV and JEV is mediated by both innate and adaptive immune responses. The RlG-1 like receptors (RLR) are cytosolic pathogen recognition receptors that recognize non-self RNA and signal through the MAVS adaptor protein to trigger innate antiviral immunity against WNV and JEV. In addition to their role in innate immunity, our laboratory recently discovered that components of the RLR pathway are critical for programming protective adaptive immune responses responsible for clearing virus during the later stages of infection. This includes MAVS-mediated regulation of humoral and cell-mediated immune responses (CD8+, CD4+ and Treg responses) as well as LGP2-mediated regulation of T cell immunity during WNV infection. LGP2 was found to function in a cell-intrinsic manner to control CD8+ T cell survival and effector properties. These findings establish that the RLRs regulate the interface between innate and adaptive immunity during flavivirus infection. However, the immunological mechanism underlying RLR regulation of T cell immunity against flavivirus infection and vaccination are not well understood. Project 4 studies will (1) determine the role of RLR signaling and function in regulating T cell priming; (2) define the Tcell intrinsic function of MAVS and LGP2 in regulating effector and memory T cell responses; (3) determine how MAVS and LGP2 function to regulate memory T cell recall responses. This work will reveal novel insights into innate immune regulation of immunological memory and identify new therapeutic targets and strategies for vaccine protection against flavivirus infection.
项目4的目标是了解在黄病毒感染期间先天免疫感知和保护性T细胞免疫反应调节之间的串扰。西尼罗河病毒(WNV)和日本脑炎病毒(JEV)是由蚊媒传播的新出现的黄病毒,在全球范围内引起病毒性脑炎的年度流行。目前还没有被批准用于人类治疗西尼罗河病毒感染的疫苗或疗法,目前预防乙脑病毒感染的疫苗也不能提供终身保护性免疫。对西尼罗河病毒和乙脑病毒的保护是由先天免疫反应和获得性免疫反应介导的。RLG-1样受体(RLR)是一种胞质病原体识别受体,识别非自身RNA,并通过MAVS接头蛋白发出信号,触发对西尼罗河病毒和乙脑病毒的先天抗病毒免疫。除了在先天性免疫中的作用外,我们的实验室最近发现,RLR途径的组成部分对于编程保护性适应性免疫反应至关重要,这些免疫反应负责在感染的后期清除病毒。这包括MAVS介导的体液和细胞免疫反应(CD8+、CD4+和Treg反应)的调节,以及在西尼罗河病毒感染过程中LGP2介导的T细胞免疫调节。LGP2被发现以细胞固有的方式发挥作用,控制CD8+T细胞的存活和效应器特性。这些发现证实,在黄病毒感染期间,RLRs调节先天免疫和获得性免疫之间的界面。然而,RLR调节T细胞免疫对抗黄病毒感染和疫苗接种的免疫学机制尚不清楚。项目4的研究将(1)确定RLR信号和功能在调节T细胞启动中的作用;(2)确定MAV和LGP2在调节效应器和记忆性T细胞反应中的T细胞固有功能;(3)确定MAV和LGP2如何调节记忆性T细胞回忆反应。这项工作将揭示免疫记忆的先天免疫调节的新见解,并确定针对黄病毒感染的疫苗保护的新治疗靶点和策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mehul Shamal Suthar其他文献
Mehul Shamal Suthar的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mehul Shamal Suthar', 18)}}的其他基金
Understanding the mechanisms of antibody-mediated transcytosis of ZIKV within the placenta
了解胎盘内抗体介导的 ZIKV 转胞吞作用机制
- 批准号:
10402864 - 财政年份:2020
- 资助金额:
$ 51.58万 - 项目类别:
Cell-intrinsic role of caspase-1 in regulating antigen-specific CD8+ T cell responses
Caspase-1 在调节抗原特异性 CD8 T 细胞反应中的细胞内在作用
- 批准号:
10171780 - 财政年份:2020
- 资助金额:
$ 51.58万 - 项目类别:
Understanding the mechanisms of antibody-mediated transcytosis of ZIKV within the placenta
了解胎盘内抗体介导的 ZIKV 转胞吞作用机制
- 批准号:
10058046 - 财政年份:2020
- 资助金额:
$ 51.58万 - 项目类别:
Understanding the mechanisms of antibody-mediated transcytosis of ZIKV within the placenta
了解胎盘内抗体介导的 ZIKV 转胞吞作用机制
- 批准号:
10624960 - 财政年份:2020
- 资助金额:
$ 51.58万 - 项目类别:
Understanding the mechanisms of antibody-mediated transcytosis of ZIKV within the placenta
了解胎盘内抗体介导的 ZIKV 转胞吞作用机制
- 批准号:
10189512 - 财政年份:2020
- 资助金额:
$ 51.58万 - 项目类别:
Identifying host genetic determinants that regulate dendritic cell activation
识别调节树突状细胞激活的宿主遗传决定因素
- 批准号:
8893467 - 财政年份:2015
- 资助金额:
$ 51.58万 - 项目类别:
Identifying host genetic determinants that regulate dendritic cell activation
识别调节树突状细胞激活的宿主遗传决定因素
- 批准号:
9094679 - 财政年份:2015
- 资助金额:
$ 51.58万 - 项目类别:
Regulation of T cell immunity by the cytosolic RIG-I like receptors
胞质 RIG-I 样受体对 T 细胞免疫的调节
- 批准号:
8897470 - 财政年份:2014
- 资助金额:
$ 51.58万 - 项目类别:
Generation of MAVS conditional KO mice to study cell-type specific immunity
生成 MAVS 条件 KO 小鼠以研究细胞类型特异性免疫
- 批准号:
8787074 - 财政年份:2013
- 资助金额:
$ 51.58万 - 项目类别:
Generation of MAVS conditional KO mice to study cell-type specific immunity
生成 MAVS 条件 KO 小鼠以研究细胞类型特异性免疫
- 批准号:
8623700 - 财政年份:2013
- 资助金额:
$ 51.58万 - 项目类别:
相似海外基金
Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
- 批准号:
23K18186 - 财政年份:2023
- 资助金额:
$ 51.58万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
- 批准号:
10560883 - 财政年份:2023
- 资助金额:
$ 51.58万 - 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10730692 - 财政年份:2021
- 资助金额:
$ 51.58万 - 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
- 批准号:
21K06459 - 财政年份:2021
- 资助金额:
$ 51.58万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10189880 - 财政年份:2021
- 资助金额:
$ 51.58万 - 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
- 批准号:
2404261 - 财政年份:2020
- 资助金额:
$ 51.58万 - 项目类别:
Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10222540 - 财政年份:2020
- 资助金额:
$ 51.58万 - 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10669717 - 财政年份:2020
- 资助金额:
$ 51.58万 - 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
- 批准号:
20K10713 - 财政年份:2020
- 资助金额:
$ 51.58万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10174522 - 财政年份:2020
- 资助金额:
$ 51.58万 - 项目类别: